Existing studies suggest that CD8+ T cells can mitigate Alzheimer’s disease progression by modulating microglial function, implying that this observed effect may offer potential therapeutic benefits.51 In conclusion, AR@ENV demonstrates favorable biosafety profiles. Here, CD8A is linked to early-onset autosomal dominant Alzheimer disease.